Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 2/2020

01-02-2020 | Thrombosis

Congenital fibrinogen disorders with repeated thrombosis

Authors: Xiuli Zhang, Chuang Zhang, Baoheng Wang, Ningheng Chen, Gaihe Sun, Xueli Guo

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2020

Login to get access

Abstract

Congenital dysfibrinogenemia is characterized with undetectable or low fibrinogen level by Clauss assay complicated by bleeding and/or thrombosis. These may lead to a diagnostic problem to some clinicians unfamiliar with this disease. We reported a case of congenital dysfibrinogenemia manifested as hemorrhage, repeated thrombosis, low fibrinogen levels through Clauss assay and but normal levels of fibrinogen through PT-derived tests. In conclusion, to patients with thrombosis complicated by decreased fibrinogen level, clinicians and laboratory physicians should be alert to the possibility of congenital dysfibrinogenemia.
Literature
1.
Naz A, Biswas A, Khan TN et al (2017) Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population. Thromb J 15:24PubMedPubMedCentralCrossRef
2.
Brennan SO, Davis RL, Mosesson MW et al (2007) Congenital hypodysfibrinogenaemia (Fibrinogen Des Moines) due to a gamma320Asp deletion at the Ca2+ binding site. Thromb Haemost 98(2):467–469PubMed
3.
Brennan SO, Chitlur M (2013) Hypodysfibrinogenemia and thrombosis in association with a new fibrinogen γ chain with two mutations (γ114Tyr-His, andγ320Asp deleted). Thromb Haemost 109(6):1180–1182PubMedCrossRef
4.
Castaman G, Giacomelli SH, Duga S et al (2008) Congenital hypofibrinogenemia associated with novel heterozygous fibrinogen Bbeta and gamma chain mutations. Haemophilia 14(3):630–633PubMedCrossRef
5.
Koopman J, Haverkate F, Briet E et al (1991) A congenitally abnormal fibrinogen (Vlissingen) with a 6-base deletion in the gamma-chain gene, causing defective calcium binding and impaired fibrin polymerization. J Biol Chem 266(20):13456–13461PubMed
6.
Terasawa F, Hogan KA, Kani S et al (2003) Fibrinogen Otsu I: a gammaAsn319, Asp320 deletion dysfibrinogen identified in an asymptomatic pregnant woman. Thromb Haemost 90(4):757–758PubMedCrossRef
7.
Santoro C, Massaro F, Venosi S et al (2016) Severe thrombotic complications in congenital afibrinogenemia: a pathophysiological and management dilemma. Semin Thromb Hemost 42(5):577–582PubMedCrossRef
8.
Zhou J, Ding Q, Chen Y et al (2015) Clinical features and molecular basis of 102 Chinese patients with congenital dysfibrinogenemia. Blood Cells Mol Dis 55(4):308–315PubMedCrossRef
9.
de Moerloose P, Casini A, Neerman-Arbez M (2013) Congenital fibrinogen disorders: an update. Semin Thromb Hemost 39(6):585–595PubMedCrossRef
10.
Chapin JC, Hajjar KA (2015) Fibrinolysis and the control of blood coagulation. Blood Rev 29(1):17–24PubMedCrossRef
11.
Haverkate F, Samama M (1995) Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 73(1):151–161PubMedCrossRef
12.
Cunningham MT, Brandt JT, Laposata M, Olson JD (2002) Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 126(4):499–505PubMed
13.
Krammer B, Anders O, Nagel HR, Burstein C, Steiner M (1994) Screening of dysfibrinogenaemia using the fibrinogen function versus antigen concentration ratio. Thromb Res 76(6):577–579PubMedCrossRef
14.
Kotlín R, Pastva O, Stikarová J, Hlaváčková A, Suttnar J, Chrastinová L et al (2014) Two novel mutations in the fibrinogen γ nodule. Thromb Res 134(4):901–908PubMedCrossRef
15.
Asselta R, Robusto M, Platé M, Santoro C, Peyvandi F, Duga S (2015) Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thromb Res 136(1):168–174PubMedCrossRef
16.
Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P (2015) Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost 13(6):909–919PubMedCrossRef
17.
Franzblau EB, Punzalan RC, Friedman KD, Roy A, Bilen O, Flood VH (2013) Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement. Pediatr Blood Cancer 60(3):500–502PubMedCrossRef
18.
Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E et al (2015) Natural history of patients with congenital dysfibrinogenemia. Blood 125(3):553–561PubMedPubMedCentralCrossRef
19.
Neerman-Arbez M, de Moerloose P, Casini A (2016) Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost 42(4):356–365PubMedCrossRef
Metadata
Title
Congenital fibrinogen disorders with repeated thrombosis
Authors
Xiuli Zhang
Chuang Zhang
Baoheng Wang
Ningheng Chen
Gaihe Sun
Xueli Guo
Publication date
01-02-2020
Publisher
Springer US
Keyword
Thrombosis
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2020
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-019-01958-y

Other articles of this Issue 2/2020

Journal of Thrombosis and Thrombolysis 2/2020 Go to the issue

OriginalPaper

Induction of tissue factor expression by anti-β2-glycoprotein I is mediated by tumor necrosis factor α

Report

A case report of severe bleeding due to lupus anticoagulant hypoprothrombinemia syndrome

OriginalPaper

Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study

ReviewPaper

Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy

ReviewPaper

The dawn of aspirin free strategy after short term dual antiplatelet for percutaneous coronary intervention: meta-analysis of randomized controlled trials

OriginalPaper

Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits